Ozempic Gastroparesis Attorney: What Documentation Supports a Claim?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Product Safety Concerns

For decades, the general health and science information landscape has served as a foundational resource for public awareness, offering broad guidance on wellness, disease prevention, and the safe use of medical products. This legacy context has helped individuals navigate complex health decisions by emphasizing evidence-based understanding and risk communication. Within this framework, the transition from general health education to specific product safety concerns is a natural progression, particularly when a widely used medication becomes associated with emerging adverse event reports. In the case of Ozempic, a medication originally prescribed for diabetes management, the public health conversation has expanded from general metabolic health to include potential gastrointestinal complications. Specifically, reports of gastroparesis—a condition characterized by delayed gastric emptying—have prompted legal and medical scrutiny. For individuals who have developed gastroparesis following Ozempic use, the question of documentation becomes central to any injury claim. Supporting evidence typically includes medical records documenting the diagnosis, prescription history, and temporal relationship between drug exposure and symptom onset. Additionally, pharmacy records, physician notes, and diagnostic test results (such as gastric emptying studies) are critical to establishing a plausible link. This shift from general health awareness to targeted documentation reflects the broader need for accountability in pharmaceutical safety, where legacy health education now meets the specific demands of product liability and patient advocacy.

Clinical Evidence Linking Ozempic to Gastroparesis

The documentation supporting an Ozempic gastroparesis injury claim centers on three core areas: the clinical presentation and diagnosis of gastroparesis, the pharmacological profile of Ozempic and its reported adverse effects, and the mechanistic pathways linking the drug to delayed gastric emptying. Additionally, the adequacy of warnings and the timeline between exposure and harm are critical for legal considerations. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules. The condition can be idiopathic or secondary to diabetes, surgery, or medications. In the context of Ozempic, the drug's mechanism of action as a glucagon-like peptide-1 (GLP-1) receptor agonist slows gastric motility, which is a known pharmacological effect. This slowing can exacerbate or induce gastroparesis in susceptible individuals. Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes and weight management. Its prescribing information documents gastrointestinal adverse reactions at frequencies higher than placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Discontinuation due to gastrointestinal adverse reactions was 0.4% for placebo, 3.1% for Ozempic 0.5 mg, and 3.8% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions with frequencies below 5% include dyspepsia (1.9% placebo, 3.5% Ozempic 0.5 mg, 2.7% Ozempic 1 mg), eructation, flatulence, gastroesophageal reflux disease, and gastritis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data establish a clear association between Ozempic and gastrointestinal dysfunction.

Real-World Evidence from FAERS Database

The FDA Adverse Event Reporting System (FAERS) database provides real-world evidence of adverse events associated with Ozempic. The most frequently reported events include nausea (8652 reports), vomiting (5578 reports), diarrhea (5274 reports), and impaired gastric emptying (2693 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). The term 'impaired gastric emptying' is directly relevant to gastroparesis, as it reflects delayed stomach emptying. Other gastrointestinal symptoms such as abdominal pain, dyspepsia, and constipation are also reported. The high volume of reports for impaired gastric emptying supports a mechanistic link between Ozempic and gastroparesis. Mechanistically, GLP-1 receptor agonists like semaglutide slow gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This effect is dose-dependent and can persist with chronic use. In susceptible patients, this pharmacological action may lead to clinically significant gastroparesis, especially if underlying conditions such as diabetes or autonomic neuropathy are present. The timeline between exposure and harm is variable; symptoms often emerge during dose escalation, as noted in clinical trials where the majority of nausea, vomiting, and diarrhea occurred during this period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, delayed onset after months of use is also possible, complicating the causal attribution.

Documentation Requirements for an Injury Claim

For an injury claim, documentation must establish that the patient used Ozempic, developed gastroparesis symptoms, and that the timeline is consistent with drug exposure. Medical records should include diagnosis codes (e.g., K31.84 for gastroparesis), gastric emptying study results, and documentation of symptom onset relative to Ozempic initiation. The prescribing information's listing of gastrointestinal adverse reactions, including dyspepsia and gastritis, may be used to argue that the manufacturer was aware of the risk of delayed gastric emptying. However, the label does not explicitly mention 'gastroparesis' as a warning, which could be a point of contention regarding adequacy of warnings. Attorney considerations include the need to demonstrate that the drug caused the injury, not an underlying condition. Expert testimony from a gastroenterologist or pharmacologist may be required to explain the mechanistic link. The FAERS data showing 2693 reports of impaired gastric emptying provides epidemiological support, but individual causation must be proven. The statute of limitations varies by jurisdiction, so prompt legal consultation is advised. In summary, documentation supporting an Ozempic gastroparesis claim includes clinical trial data showing increased gastrointestinal adverse reactions, FAERS reports of impaired gastric emptying, and medical records linking symptom onset to drug use. The adequacy of warnings is questionable given the absence of explicit gastroparesis labeling, and the timeline of exposure is critical for establishing causation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What medical records are needed to prove an Ozempic gastroparesis claim?

You need medical records documenting a gastroparesis diagnosis (e.g., ICD-10 code K31.84), results from gastric emptying studies, prescription records showing Ozempic use, and physician notes linking symptom onset to the medication. Pharmacy records and a timeline of exposure are also critical.

Does the Ozempic label warn about gastroparesis?

The prescribing information lists gastrointestinal adverse reactions like dyspepsia and gastritis but does not explicitly mention 'gastroparesis.' This omission may be used to argue inadequate warnings. However, the label does note that GLP-1 agonists slow gastric emptying, which is the mechanism behind gastroparesis.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.